# V98 Independent Phase1073 — S signed execution oracle preregistration (2026-10-23)

**Before S economics and independently of any S PnL:** implement an isolated S-native signed, 16-corner execution solver. This is portfolio survival infrastructure, not alpha selection, and does not alter rejected Q/R candidates.

- Four signed positions, pre-trade cash/units, t+1 opening execution of t-1 S targets; fixed asset .45, gross 1.35, net .75, stressed equity floor .25. Include 16 high/low shock corners plus baseline, transaction fee and pre-funded conservative native funding reserve.
- Solve a deterministic linear program in pre-trade equity units to minimize target deviation (primary) and turnover (secondary). Cap each asset's absolute executed turnover at 1% of **t-1** quote volume for capacity_1m/10m; immediate mode has no capacity cap. No future volume, future mark or future funding used for order sizing.
- Explicit fail-closed on infeasible LP, source-shape error, nonfinite inputs, breached caps, post-solve stress violation. No hidden leverage, no silent target alteration, no post-result optimization.
- Test zero target, long/short signs, funding buffer, 16-corner invariants, capacity and adversarial stress. A passing synthetic test is not evidence of CAGR or an economic promotion.
- Source gate Phase1071–1072 remains a prerequisite to freezing S and any historical PnL. The future 90-cell evaluation uses only preregistered base/severe/supersevere fee tiers, two funding orderings, three capital modes and five paths.

No 2025 validation, 2026+, XRP, Phase083 or V14/V15/V99 access.